The online version of this article (https://doi.org/10.1186/s12886-018-0807-1) contains supplementary material, which is available to authorized users.
Conbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD). This systematic review aims to assess the efficacy and safety of conbercept in the treatment of wet AMD.
PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP database, and Wanfang database were searched from their earliest records to June 2017. We included randomized controlled trials (RCTs) evaluating the efficacy and safety of conbercept in wet AMD patients. Outcomes included the mean changes from baseline in best-corrected visual acuity (BCVA) score (primary outcome), central retinal thickness (CRT), plasma level of vascular endothelial growth factor (VEGF) over time, and the incidence of adverse events (AEs).
Eighteen RCTs (1285 participants) were included in this systematic review. Conbercept might improve BCVA compared to triamcinolone acetonide [MD = 0.11, 95% CI (0.08, 0.15)], and reduce CRT compared to the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide). The incidence of AEs in patients receiving conbercept was significantly lower than those receiving triamcinolone acetonide [RR = 0.25, 95% CI (0.09–0.72)], but was similar to the other therapies. Conbercept seemed to be more effective than ranibizumab in lowering the plasma level of VEGF [MD = − 15.86, 95% CI (− 23.17, − 8.55)].
Current evidence shows that conbercept is a promising option for the treatment of wet AMD. Nevertheless, further studies are required to compare the efficacy, long-term safety and cost-effectiveness between conbercept and other anti-VEGF agents in different populations.
Additional file 1: Table S1. PRISMA 2009 Checklist. Table S2. Searching Strategy. (DOC 65 kb)12886_2018_807_MOESM1_ESM.doc
American academy of ophthalmology. Age-Related Macular Degeneration PPP-Updated 2015. Available at: https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015.
Solomon SD, Lindsley K, Vedula SS, Krzystolok MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139. PubMedCentral
Higgins J, Green S. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. Available at: http://handbook.cochrane.org/.
Li YY. Analysis of efficacy and safety of conbercept in treatment of AMD. For all health 2017; 11: 104–105.
Mei HY. Observation of the effectiveness of conbercept in treatment of wet AMD. Chinese and Foreign Medical Research. 2017;15:32.
Song W, Zhao S, Zhi Y, Cheng LN. Clinical observation of intravitreal injection of conbercept treating exudative age-related macular degeneration. Int Eye Sci. 2016;16:1310–2.
Liu ZN, Sun XH. Clinical efficacy of conbercept in the treatment of AMD. World Clin Med. 2016;10:120–4.
Zhang HX, Zhao NN. Effect of conbercept and lucentis on serum CRP, VEGF and CMT, CNV, IOP in age-related macular degeneration. Chin J Biochem Pharm. 2016;36:134–6.
Liu R, Liu CM, Li N, Zhou Z, Wei XD, Cui LL. Effect of conbercept ophthalmic injection on peripheral blood vascular endothelial growth factor, intraocular pressure and visual acuity in patients with age related macular degeneration. Chin J Biochem Pharm. 2015;35:104–6.
Wang NF. Comparison of ranibizumab vs conbercept in the treatment of wAMD. China Health Care Nutr. 2017;27:192–3.
Lyu P, Xu H, Wang Q, Zhou J, Li ZQ, Chen YH, et al. Comparison of the clinical effectiveness of ranibizumab and conbercept in the treatment of wAMD. J Community Med. 2016;14:30–1.
Zheng MW. Effect comparative observation of conbercept and ranibizumab in the treatment of age-related macular degeneration. J Math Med. 2017;30:228–30.
Wang XX. Use of conbercept injection in treatment of AMD. The World of Mother and Baby. 2015;24:51.
Qin MM, Chen Y, Xie MN, Li H. Efficacy and safety of conbercept in treating exudative senile macular degeneration. Chin J Clin Pharm. 2016;25:367–70.
Li L, Xue JL. Su J. Clinical observation of the effectiveness of conbercept injection in the treatment of AMD. Strait. Pharm J. 2017;29:77–9.
Zhang X. Clinical observation on conbercept ophthalmic injection for treating age-related macular degeneration in 49 cases. China Pharm. 2015;24:21–3.
Zhu Y, Du SS, Tian F. Intravitreal injection conbercept in treatment of AMD. Shanxi Med J. 2017;46:262–3.
He XT, Wang DL, Zhang H, He HN. Clinical study of conbercept intravitreal injection for the treatment of wet age-related macular degeneration. Int Eye Sci. 2015;15:1603–5.
Han X, Chang Y, Wang J. Effect of conbercept in the treatment of high altitude area patients with senile macular degeneration. Int Eye Sci. 2017;17:104–6.
Pan XL, Pan Y, Hong WW, Zhao HY. Clinical observation of intravitreal injection conbercept in treatment of wAMD. Chin J Convalescent Med. 2017;26:212–3.
Yue JL. The effect of intravitreal injection conbercept on the vision and daily life of patients with wAMD. J Shandong Medical College. 2017;39:226–8.
Cui J, Sun D, Lu H, Dai R, Xing L, Dong H, et al. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye. 2017:1–9. https://doi.org/10.1038/eye.2017.187.
Zhang CH. Comparison of ranibizumab and conbercept in the treatment of AMD. J Clin Med. 2016;3:10428.
- Conbercept for patients with age-related macular degeneration: a systematic review
- BioMed Central